000167754 001__ 167754
000167754 005__ 20240229133547.0
000167754 0247_ $$2doi$$a10.1177/0300891621996805
000167754 0247_ $$2pmid$$apmid:33641520
000167754 0247_ $$2ISSN$$a0300-8916
000167754 0247_ $$2ISSN$$a2038-2529
000167754 037__ $$aDKFZ-2021-00518
000167754 041__ $$aEnglish
000167754 082__ $$a610
000167754 1001_ $$00000-0002-5355-3173$$aLang, Kristin$$b0
000167754 245__ $$aRetrospective analysis of outcome and toxicity after postoperative radiotherapy in patients with squamous cell carcinoma of the lip.
000167754 260__ $$aThousand Oaks, Calif.$$bSage Publishing$$c2022
000167754 3367_ $$2DRIVER$$aarticle
000167754 3367_ $$2DataCite$$aOutput Types/Journal article
000167754 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1649166974_16168
000167754 3367_ $$2BibTeX$$aARTICLE
000167754 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000167754 3367_ $$00$$2EndNote$$aJournal Article
000167754 500__ $$a#LA:E050# / 2022 Apr;108(2):125-133
000167754 520__ $$aCarcinomas of the lips are a relatively common malignancy of the head and neck region, accounting for roughly one quarter of all oral cavity cancers. Compared to other oral cancer sites, this location has a favorable prognosis, with 5-year survival rates between 85% and 95%. This study summarizes our institutional experience in utilizing postoperative radiation for patients with squamous cell carcinoma of the upper and/or lower lip following incomplete surgical resection or positive lymph node involvement with extracapsular extension.We retrospectively reviewed the medical records of all patients at the University Hospital of Heidelberg between 2005 and 2018 treated with postoperative radiotherapy of the upper and lower lip. Nineteen patients were identified with a median age at diagnosis of 67 years (range, 41-95 years), with 58% male and 42% female patients. Fourteen patients (73.7%) underwent neck dissection, with 5 (35.7%) found to have extracapsular extension (ECE) and positive resection margin (R1/2), 2 (14.3%) only ECE, and 7 (50.0%) with only R1/2. All patients received a median cumulative dose of 66.0 Gy (range, 60.0-70.0 Gy) in a median of 2.0 Gy per fraction (range, 1.8-2.2 Gy).Median follow-up was 5.2 years. The median progression-free survival (PFS) was 3.9 years (range, 0.2-12.4 years), local disease-free survival (LDFS) was 4 years (range, 1-12 years) and overall survival (OS) was 5.2 years (range, 0.2-12.4 years). The 5-year Kaplan-Meier estimates for OS, PFS, and LDFS were 61.4%, 85.7%, and 100.0%, respectively. At last follow-up, 13 patients (68.4%) were still alive. Although no patient developed locoregional relapse, two patients developed distant relapse at a median of 15 months after radiotherapy. There was a statistically significant improvement in OS in patients treated with higher radiotherapy doses (>60.0 Gy, p = 0.044) compared to lower radiotherapy doses. PFS was significantly improved among patients who had N0 disease, with a negative resection margin, without ECE, and who were treated with intensity-modulated radiotherapy to doses >60.0 Gy. No grade 3/4 toxicity was detected; the most common grade 1/2 toxicities included dermatitis (n = 11, 57.9%), oral mucositis (n = 8, 42.1%), and dysphagia (n = 8, 42.1%).Our results demonstrate excellent local control and OS with acceptable toxicity when utilizing postoperative radiotherapy in patients with squamous cell carcinoma of the upper and lower lip, despite unfavorable characteristics (advanced T or N stage and/or ECE).
000167754 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000167754 588__ $$aDataset connected to CrossRef, PubMed,
000167754 650_7 $$2Other$$aHead and neck cancer
000167754 650_7 $$2Other$$aextracapsular spread
000167754 650_7 $$2Other$$alocal control
000167754 650_7 $$2Other$$asquamous cell carcinoma
000167754 7001_ $$aAkbaba, Sati$$b1
000167754 7001_ $$aHeld, Thomas$$b2
000167754 7001_ $$aEl Shafie, Rami$$b3
000167754 7001_ $$aFarnia, Benjamin$$b4
000167754 7001_ $$aBougatf, Nina$$b5
000167754 7001_ $$aBernhardt, Denise$$b6
000167754 7001_ $$aFreudlsperger, Christian$$b7
000167754 7001_ $$aPlinkert, Peter K$$b8
000167754 7001_ $$aRieken, Stefan$$b9
000167754 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b10$$udkfz
000167754 7001_ $$0P:(DE-HGF)0$$aAdeberg, Sebastian$$b11$$eLast author
000167754 773__ $$0PERI:(DE-600)2267832-3$$a10.1177/0300891621996805$$gp. 030089162199680 -$$n3$$p125-133$$tTumori journal$$v108$$x2038-2529$$y2022
000167754 909CO $$ooai:inrepo02.dkfz.de:167754$$pVDB
000167754 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000167754 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000167754 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000167754 9130_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000167754 9141_ $$y2021
000167754 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000167754 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-29
000167754 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000167754 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2022-11-12$$wger
000167754 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000167754 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000167754 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000167754 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-12
000167754 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-12
000167754 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTUMORI J : 2021$$d2022-11-12
000167754 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-12
000167754 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-12
000167754 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000167754 980__ $$ajournal
000167754 980__ $$aVDB
000167754 980__ $$aI:(DE-He78)E050-20160331
000167754 980__ $$aUNRESTRICTED